Optimizing bone health and minimizing skeletal morbidity in men with prostate cancer

Hematol Oncol Clin North Am. 2013 Dec;27(6):1261-83, ix. doi: 10.1016/j.hoc.2013.08.009. Epub 2013 Sep 20.


Maintaining bone health is important in the management of men with prostate cancer. Patients receiving androgen deprivation therapy are at increased risk for treatment-related osteoporosis, and patients with bone metastases are at increased risk for skeletal morbidity related to debilitating skeletal-related events (SREs). Optimizing bone health in these patients includes lifestyle modifications, calcium/vitamin D supplementation, and osteoclast-targeted agents in select high-risk patients. No agent is approved for the prevention of bone metastases. Novel systemic agents have shown a beneficial effect bone by directly affecting tumor growth. Integration of these anticancer agents with osteoclast-targeted agents warrants further investigation.

Keywords: Androgen deprivation therapy; Bisphosphonate; Bone metastases; Denosumab; Osteoporosis; Prostate cancer; Skeletal-related events; Zoledronic acid.

Publication types

  • Review

MeSH terms

  • Antineoplastic Agents / adverse effects
  • Antineoplastic Agents / therapeutic use
  • Bone Density Conservation Agents / therapeutic use
  • Bone Neoplasms / prevention & control
  • Bone Neoplasms / secondary*
  • Bone Neoplasms / therapy
  • Bone and Bones / physiology
  • Humans
  • Male
  • Molecular Targeted Therapy
  • Orchiectomy
  • Osteoporosis / etiology*
  • Prostatic Neoplasms / complications*
  • Prostatic Neoplasms / pathology*
  • Prostatic Neoplasms / therapy
  • Radiopharmaceuticals / therapeutic use


  • Antineoplastic Agents
  • Bone Density Conservation Agents
  • Radiopharmaceuticals